Cue Biopharma bets on anti-IgE with $691.5M Ascendant-221 deal

Cue Biopharma said on April 30 that it has licensed Ascendant-221, a clinical-stage anti-IgE monoclonal antibody, from Ascendant Health Sciences in a deal worth about $691.5 million, including a $15 million upfront payment and up to $676.5 million in development, regulatory, and commercial milestones, plus tiered royalties. The agreement gives Cue global rights outside Greater China, and the company said it plans to move Ascendant-221 into a global Phase 2b food allergy trial after data from an Ascendant-led Phase 2 chronic spontaneous urticaria study in China expected in the second half of 2026. Cue is positioning the asset as a differentiated, “dual-mechanism” anti-IgE therapy designed both to neutralize free IgE and reduce new IgE synthesis. (globenewswire.com)

Why it matters: For veterinary professionals, this is a human-biopharma deal, not an animal health launch, but it’s still worth watching because anti-IgE biology remains highly relevant across allergic disease. Food allergy treatment is a fast-moving area, especially after FDA approval of omalizumab for IgE-mediated food allergy in 2024, and new entrants are trying to improve durability, dosing convenience, or efficacy in patients with very high IgE levels. That broader immunology momentum can eventually shape companion-animal R&D thinking around allergic disease, atopy, and biologics strategy. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next key inflection point is the China Phase 2 urticaria readout in 2H 2026, which Cue says will inform whether it advances Ascendant-221 into a global Phase 2b food allergy study. (stocktitan.net)